Get the Stockscreener App
29.20
1.12%
-0.33
After Hours:
29.27
0.07
+0.24%
Lenz Therapeutics Inc stock is traded at $29.20, with a volume of 159.80K.
It is down -1.12% in the last 24 hours and up +9.65% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$29.53
Open:
$29.31
24h Volume:
159.80K
Relative Volume:
0.67
Market Cap:
$821.98M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-5.2168
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
+3.64%
1M Performance:
+9.65%
6M Performance:
-17.98%
1Y Performance:
+88.27%
1-Day Range:
$28.51
$29.77
1-Week Range:
$28.14
$30.14
52-Week Range:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
29.20 | 793.02M | 0 | -69.47M | -73.92M | -5.5973 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Holdings Decreased by Ameriprise Financial Inc. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Analysts - Defense World
LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks
7,447 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by D. E. Shaw & Co. Inc. - Defense World
LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision - Investing.com Canada
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics Showcases Revolutionary Eye Drop Treatment at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Northern Trust Corp Raises Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss - insights.citeline.com
Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN
Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Tower Research Capital LLC TRC Has $54,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment - BioSpectrum Asia
LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment - Yahoo Finance
Raymond James Financial Inc. Takes $245,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Leerink Partnrs Analysts Raise Earnings Estimates for LENZ - Defense World
HC Wainwright Issues Negative Estimate for LENZ Earnings - Defense World
Leerink Partnrs Has Negative Outlook of LENZ FY2028 Earnings - Defense World
LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Positive Estimate for LENZ FY2029 Earnings - Defense World
Lenz Therapeutics inks $125M licensing deal with Lotus - Axios
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by Wells Fargo & Company MN - Defense World
LENZ Grants Lotus Licensing Rights to Presbyopia Treatment in South Korea, Southeast Asia - marketscreener.com
LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia - The Manila Times
Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive - Investing.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of “Buy” by Brokerages - Defense World
LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Market Recap Check: LENZ Therapeutics Inc (LENZ)’s Negative Finish at 25.89, Up/Down -11.03 - DWinneX
LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times
First-Ever Presbyopia Eye Drop Treatment: LENZ Therapeutics Reveals Latest Progress at BofA Conference - Stock Titan
Barclays PLC Increases Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
JPMorgan Chase & Co. Purchases 2,643 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Renaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Legal & General Group Plc Has $252,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 - The Manila Times
LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq
Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan
Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight - The Globe and Mail
ProfittoPath - TradingView
LENZ Therapeutics Inc (LENZ)’s stock chart: A technical perspective - uspostnews.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World
Notable Wednesday Option Activity: LENZ, CVNA, APPN - Nasdaq
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Alliancebernstein L.P. - Defense World
13,280 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Alliancebernstein L.P. - Defense World
LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World
Before Buying LENZ Therapeutics Inc (NASDAQ: LENZ) Stock, Read This First - Stocksregister
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Piper Sandler - Defense World
Form 424B3 LENZ Therapeutics, Inc. - StreetInsider
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):